|
|
|
| home > pmps > autumn 2003 > production of blow fill seal container closure systems for pharmaceutical application |
|
|
 PUBLICATIONS |
Pharmaceutical Manufacturing and Packing Sourcer
|
Blow fill seal containers are a commonly used system for pharmaceutical infusion and injection solution application, and blow fill seal packaging systems are customer specific machines. An important characteristic of the blow fill seal process is the sterile and pyrogenfree moulding of bottles or ampoules directly from the extruded PE or PP in water-cooled blow moulds with an immediate sterile filling of product, and followed by a hermetic sealing of the container in one step and under aseptic conditions in the same machine. This assures high reliability as well as product security. The flexible design of the containers, which combine integrated moulding of the head closure and in-mould coding, allows for a high degree of convenience in user handling. The technology is well-known for its very low particulate matter production and neutrality to the filling product.
The materials used to manufacture blow fill seal containers are primary packaging materials suitable for storing infusion solutions until they are administered. A closure system which will make the connection between the bottle and the infusion set or a syringe is essential. The sealing between the infusion set and the bottle is important for the closure system, as is the handling of the opening system. Additionally, an issue to be aware of is the rubber or TPE disc implemented in the bottle pack cap, which acts as a barrier product for the patient. There are many different systems on the market, and this article will concentrate on the standard Euro bottle pack cap according to the ISO 15759, exploring different types of rubber discs.
|
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
News and Press Releases |
 |
A new market reference added to Safe’n’Sound®, our passive safety device platform
Safe’n’Sound® is on the market in Europe with a newly registered injectable medication.
The commercial launch of HULIO™ (Adalimumab Biosimilar) was initiated in selected European markets on October 19,2018.
Hulio™, developed by Fujifilm Kyowa Kirin Biologics Co., Ltd. and marketed in the European Union by Mylan N.V. is approved as a biosimilar for the same indications as the reference product, Humira®.
More info >> |
|
 |
White Papers |
 |
|
The Power of Execution in Clinical Research
Medpace
Medpace, long known for its excellence in conducting Phase I-IV studies
on a global platform, is particularly noted for its therapeutic
excellence. When that expertise is combined with operational precision,
the results are nothing short of stellar. The Medpace full-service
outsourcing approach – combined with therapeutic expertise, regulatory
know how, and global presence – delivers clinical studies with an
industry recognized track record.
More info >> |
|
 |
Industry Events |
 |
CPhI & P-MEC India
26-28 November 2019, India Expo Centre, Greater Noida, Delhi NCR, India
As
the pharma
industry looks increasingly towards India forhigh quality, low cost pharma solutions, CPhI & P-MEC Indiais the ideal event for companies wanting to pick up on the latest trends and innovations the market has to offer.
At
CPhI & P-MEC India, you will meet the movers and shakers from India’s
pharma machinery, technology and ingredients industries, giving you a
competitive advantage that will help grow your business.
More info >> |
|
|
